ClinicalTrials.gg
CompletedNCT04576728ESsCOVIDUpdated Jan 10, 2023

Efficacy and Safety of Trimodulin in Subjects With Severe COVID-19

A Phase 2 interventional study of Trimodulin and Placebo (human albumin 1%) in Covid19, sponsored by Biotest. Completed at 17 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-10.

Sponsored by Biotest (part of Grifols) · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
166
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 144 studies in COVID-19 with a site in Russian Federation — 4 open to participants now, 9 under way, 1 of them phase 3. COVID-19 · Russian Federation.

Enrollment
58th of 105
166 · median 198
Started
2020
with 85 others
Phase 2
19 of 144
none open now
Registered
46th of 144
by date

Among the 144 studies in COVID-19 with a site in Russian Federation, this one is the 58th largest by enrollment of the 105 interventional ones that give a count, is one of 86 that started in 2020, is one of 19 in phase 2, and was the 46th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

4 of the 144 studies in COVID-19 with a site in Russian Federation are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Russian Federation have not opened yet or have stopped. Only those recruiting at a site in Russian Federation →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 144 studies in COVID-19 with a site in Russian Federation, or all of them as a file.
02

Study summary

The objectives of the trial are to evaluate the efficacy and safety of trimodulin as add-on therapy to standard of care (SoC) compared to placebo treatment in adult hospitalized subjects with severe COVID-19.

Additionally, pharmacodynamic (PD) and pharmacokinetic (PK) properties of trimodulin will be evaluated in all subjects.

Read the detailed description

This is a randomized, placebo-controlled, double-blind, multi-center, phase II trial investigating the efficacy and safety of trimodulin compared to placebo treatment, as add-on therapy to SoC in adult subjects with severe COVID-19. Severe COVID-19 patients with need for non-invasive ventilation or high flow oxygen and with dysregulated inflammatory responses demonstrated by an elevated CRP level, will be enrolled.

Subjects will be randomized to receive either trimodulin or placebo on a 1:1 basis, stratified by center. Investigational Medicinal Product (IMP) treatments will be blinded. Subjects will be administered IMP once daily on five consecutive days (day 1 through day 5) as add-on therapy to SoC. The subsequent follow-up phase comprises 23 [+3] days (day 6 through day 28) followed by an end-of-trial visit/ telephone call on day 29 [+3]. For evaluation of this trial, a 9-category ordinal scale will be used. The primary aim of trimodulin treatment in the enrolled severely ill patients with a score of 5, is to prevent their clinical deterioration to a critical disease stage (score 6-7, e.g. requiring invasive mechanical ventilation or ECMO) and death (score 8). Accordingly, a composite primary efficacy endpoint reflecting the deterioration / mortality rate is used.

03

Conditions studied

  • Covid19

Keywords

  • Covid19
  • Severe community acquired pneumonia
  • Acute Respiratory Distress Syndrome
  • SARS-CoV-2
  • Severe Corona Virus Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written obtained from the subject or legally authorized representative or informed verbal or administration consent due to pandemic situation, in compliance with all local legal requirements.
  2. Male or female subject ≥18 years of age.
  3. Laboratory-confirmed SARS-CoV-2 infection from a test done in a respiratory tract sample within the last 5 days at screening.
  4. Diagnosis of community-acquired severe COVID-19 within 10 days after hospital-admission, with severe defined as:

    Need for non-invasive ventilation (NIV), or high-flow oxygen therapy (score =5 on the 9-category ordinal scale).

    At least one of the following clinical respiratory parameters is fulfilled: dyspnea, respiratory frequency ≥30/min, SpO2 ≤93%, 100 mmHg \< PaO2/FiO2 ≤300 mmHg, and/or lung infiltrates >50% within 24 to 48 hours.

    At least one measurement of C-reactive protein ≥50 mg/L within 36 hours prior to start of treatment.

  5. Subject must receive SoC treatment for COVID-19.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or lactating women.
  2. Subjects that deteriorated to score >5 on the 9-category ordinal scale (e.g. receiving invasive mechanical ventilation (IMV), and/or extracorporeal membrane oxygenation (ECMO)) or subjects that improved to score \<5 prior to randomization.
  3. Severe neutropenia ( \<500/mm³) assessed within 24 hours prior to start of treatment.
  4. Thrombocytopenia ( count \<30,000/mm³) assessed within 24 hours prior to start of treatment.
  5. \<7g/dL assessed within 24 hours prior to start of treatment.
  6. Known hemolysis.
  7. Known thrombosis or thromboembolic events (TEEs) or known medical history of TEEs (e.g. cerebrovascular accidents, , myocardial infarction, pulmonary embolism, and deep vein thrombosis) within the previous 3 months or those subjects particularly at risk for TEEs (e.g. history of thrombophilia, permanent immobilization, or permanent paralysis of the lower extremities) caused by other reasons than COVID-19.
  8. Subject on dialysis or with severe renal impairment, estimated (eGFR) \<30 mL/min/1.73 m² assessed within 24 hours prior to start of treatment (details in Appendix 3: Estimated Glomerular Filtration Rate).
  9. Subject with end stage renal disease (ESRD), or known primary focal segmental glomerulosclerosis (FSGS).
  10. Known severe lung diseases interfering with COVID-19 therapy (e.g. severe interstitial lung disease, cystic fibrosis, idiopathic pulmonary fibrosis, active tuberculosis, chronically infected bronchiectasis, or active lung cancer).
  11. Known decompensated heart failure ( class III-IV).
  12. Known pre-existing hepatic cirrhosis, severe hepatic impairment ( C score ≥9 points), or hepatocellular carcinoma.
  13. Known intolerance to proteins of human origin or known allergic reactions to components of trimodulin.
  14. Selective, absolute immunoglobulin A (IgA) deficiency with known antibodies to IgA.
  15. Known treatment for thorax/head/neck/hematologic in the last 12 months.
  16. Known infection.
  17. of less than 90 days, according to the Investigator's clinical judgment, because of medical conditions neither related to COVID-19 nor to associated medical complications.
  18. Obesity ( ≥40 kg/m²), a body weight of more than 123 kg, or anorexia (body mass index \<16 kg/m²).
  19. Known treatment other than acute treatment for COVID-19 (e.g. transplant recipient, subject with disease).
  20. Known treatment with polyvalent immunoglobulin preparations, any type of blood product, or any type of interferon during the last 21 days before entering the trial.
  21. Participation in another interventional clinical trial within 30 days before entering, or during the trial, or previous participation in this clinical trial.
  22. Employee or direct relative of an employee of the contract research organization, the trial site, or Biotest.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
166 participants (actual)

Study arms

  • Experimental
    Trimodulin

    Trimodulin (human IgM, IgA, IgG solution) for intravenous (IV) administration.

    Drug: Trimodulin

  • Placebo comparator
    Placebo

    Human albumin 1%

    Other: Placebo (human albumin 1%)

Interventions

  • IMP will be administered via IV infusion on 5 consecutive days.

    Also known as: BT588

  • OtherPlacebo (human albumin 1%)

    IMP will be administered via IV infusion on 5 consecutive days.

06

What researchers measure

Primary outcomes

  1. Clinical detoriation rate

    Percentage of subjects with a change of clinical status to score 6 or 7 on the 9-category ordinal scale

    Time frame: Between day 6 and day 29

  2. 28-day all-cause mortality rate

    Percentage of subjects with a change to score 8 on the 9-category ordinal scale

    Time frame: Between day 1 and day 29

Secondary outcomes

  1. Clinical deterioration rate

    Percentage of subjects with a change to score 6-7

    Time frame: Days 1-29 and days 6-29

  2. 28-days all-cause mortality rate on day 29

    Percentage of subjects with score=8, assessed at the end-of-trial visit on day 29 \[+3\].

    Time frame: Day 29

  3. Time to clinical deterioration

    Number of days to first change from score 5 (enrollment) to score 6-7

    Time frame: Time Frame: between Days 1-29 and days 6-29

  4. Time to Mortality

    Number of days to change to score =8

    Time frame: Time Frame: between Day 1 and day 29

  5. Proportion of subjects in each of the 9-categories of the ordinal scale

    Number of patients by score on specific study days

    Time frame: Days 7, 14, 21, 29

  6. Time to clinical improvement

    Number of days to change to score 4 (mild disease, with supplemental oxygen) or score 3 (mild disease, no supplemental oxygen)

    Time frame: Day 29

  7. Proportion of subjects with score ≤2

    Proporation of subjects that improved to score ≤2

    Time frame: Day 29

  8. Days on IMV

    Number of calendar days on IMV until day 29

    Time frame: Until day 29

  9. Days without oxygen supply

    Number of calendar days without any form of oxygen support until day 29

    Time frame: Until day 29

  10. Time to discontinuation from any form of oxygen supply

    Time to definite stop of any form of additional oxygenation, irrespective of short interruptions

    Time frame: Until day 29

  11. Proportion of subjects without any form of oxygen supply

    Proportion of subjects that improved to not requiring supplemental oxygen.

    Time frame: Day 29

  12. Hospital-free-days

    Calendar days between hospital discharge and day 29

    Time frame: Until day 29

  13. SARS-CoV-2 status

    Time to SARS-CoV-2 negative status

    Time frame: Until day 29

  14. Adverse events (AEs), treatment-emergent AEs (TEAEs), AEs of special interest, infusional TEAEs

    Number, severity, causality, outcome, and seriousness of all. AE, TEAEs that led to permanent withdrawal of IMP, and TEAEs that led to discontinuation of the trial.

    Time frame: Until day 29

  15. TEAEs

    Number of all infusion related TEAEs

    Time frame: Until day 29

  16. SAEs

    Number, severity, causality, and outcome of all SAEs

    Time frame: Until day 29

  17. Dose modifications

    Dose modifications (incl. reductions and changes in infusion rate)

    Time frame: Day 1-5

  18. Time to recovery

    Number of days to change to score ≤2 (hospital discharged or meets discharge criteria)

    Time frame: Day 29

  19. Change over time in ECG parameters

    ECG recordings, (including heart rate, PR interval, RR interval, QRS interval, QT-interval, QTcF) showing abnormal, clinically relevant findings will be reported as adverse event.

    Time frame: Until day 29

  20. Change over time in vital signs

    Changes in recordings of vital sign parameters (including systolic and diastolic blood pressure, Arterial oxygen saturation, heart rate, respiratory rate and body temperature) showing clinically significant measurements outside the normal range will be reported as adverse event.

    Time frame: Until day 29

Other outcomes

  1. Pharmacokinetic assessment of immunoglobulins

    Assessment of changes in serum concentrations (g/L) of IgM, IgA, and IgG before, during and after treatment.

    Time frame: Day 1(baseline) to day 29

  2. Pharmacodynamic assessment of disease related serum proteins

    Assessment of relative changes in serum concentrations from baseline before, during and after treatment including inflammation markers (e.g. % change in CRP, PCT, Ferritin, TNF-alpha, IL-6, IL-8 and IL-10), biomarkers (e.g. % change in p-selectin) and complement factors (e.g. % change in C3, C4).

    Time frame: Day 1(baseline) to day 29

07

Study locations

17 sites
  • Investigational site # 5503
    Porto Alegre, 90020-090, Brazil
  • Investigational site # 5502
    Santo André, 09030-010, Brazil
  • Investigational site # 5505
    Santo André, 09080-110, Brazil
  • Investigational site # 5501
    São Paulo, 05403-000, Brazil
  • Investigational site # 3304
    Paris, 75020, France
  • Investigational Site # 3301
    Paris, 75877, France
  • Investigational site # 3305
    Saint-Étienne, 42 055, France
  • Investigational site # 0707
    Kemerovo, 650066, Russian Federation
  • Investigational site # 0709
    Krasnoyarsk, 660062, Russian Federation
  • Investigational site # 0702
    Moscow, 111539, Russian Federation
  • Investigational site # 0706
    Moscow, 119048, Russian Federation
  • Investigational site # 0711
    Moscow, 125015, Russian Federation
  • Investigational Site # 0704
    Moscow, 125367, Russian Federation
  • Investigational site # 0708
    Moscow, 129301, Russian Federation
  • Investigational site # 0701
    Saint Petersburg, 197706, Russian Federation
  • Investigational Site # 3401
    Barcelona, Spain
  • Investigational Site # 3402
    Madrid, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in Jun 2021, 8 months.

Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's 8 months is close to that.

Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2020
First posted
Oct 6, 2020
StartActual
Oct 6, 2020
Primary completionActual
Jun 29, 2021
CompletionActual
Jun 29, 2021
Last update
Jan 10, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 10, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04576728
Lead sponsor
Biotest
Responsible party
Sponsor
First posted
Oct 6, 2020
Start date
Oct 6, 2020
Primary completion
Jun 29, 2021
Completion
Jun 29, 2021
Last update
Jan 10, 2023

Study contacts

Antoni Torres, MD
principal investigator · University of Barcelona Hospital Clinic of Barcelona Spain

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trimodulin

Start the discussion